00954 CHANGMAO BIO
- 0.430
- +0.030+7.50%
CHANGMAO BIO News
常茂生物：年報 2023
Changmao Biotech (00954.HK) received 1.98 million shares from Chairman Rui Xinsheng
Gelonghui, April 8 | According to the latest equity disclosure data of the Stock Exchange, from April 2 to April 3, 2024, Changmao Biotech (00954.HK) was granted a total increase of 1.8 million shares by executive director Rui Xinsheng (Chairman) at an average price of HK$0.3796-0.38 per share on the market, involving about HK$750,000. After increasing its holdings, Rui Xinsheng's latest shareholding was 9.34 million shares, and the shareholding ratio increased from 4.01% to 5.08%.
Market Cool On Changmao Biochemical Engineering Company Limited's (HKG:954) Revenues Pushing Shares 28% Lower
To the annoyance of some shareholders, Changmao Biochemical Engineering Company Limited (HKG:954) shares are down a considerable 28% in the last month, which continues a horrid run for the company.
Changmao Biotech (00954) announced annual results. Shareholders' losses of 86.057 million yuan were converted from profit to loss year-on-year
Changmao Biotech (00954) announced its annual results for the year ended December 31, 2023. The group received revenue...
CHANGMAO BIO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
SDIC Securities: The food and beverage industry is resilient and clearly actively recommends companies with changing competitiveness during the off-peak season
China Investment Securities believes that sector valuations are still at the bottom, excellent companies can still have excess profits, and continue to recommend the sector.
Changes in Hong Kong stocks | Changmao Biotech (00954) fell more than 21% last year's pre-loss of more than 85 million yuan, and the company suspended implementation of the proposed A-share issuance plan
Chang Mao Biotech (00954) fell by more than 21%. As of press release, it was down 21.7% to HK$0.415, with a turnover of HK$1.092 million.
Changmao Biochemical Engineering Had Plans to List on Shenzhen Stock Exchange
Changmao Biochemical Engineering Had Plans to List on Shenzhen Stock Exchange
Changmao Biochemical Engineering: Suspending IPO Plan Due to Current Macro Economic Environment
Changmao Biochemical Engineering: Suspending IPO Plan Due to Current Macro Economic Environment
Chang Mao Biotech (00954): Plans to publicly issue RMB common shares and list them on the Shenzhen Stock Exchange GEM have not been implemented
Zhitong Finance App News, Chang Mao Biotech (00954) issued an announcement. As of the date of this announcement, the company's plan to publicly issue RMB common shares (A shares) and list them on the Shenzhen Stock Exchange GEM has not been implemented (recommended plan).
Changmao Biotech (00954) is forecasting an annual net loss of about 85 million yuan to 95 million yuan year-on-year profit and loss
Changmao Biotech (00954) issued an announcement. The Group expects to acquire ownership for the year ended December 31, 2023...
Changmao Biotech (00954.HK) received an increase of 196,000 shares from Chairman Rui Xinsheng
Glonghui November 28 | According to the latest equity disclosure data from the Stock Exchange, on November 24, 2023, Changmao Biotech (00954.HK) received an increase of 196,000 shares in the market by an average price of HK$0.548 per share, involving approximately HK$107,400, by executive director Rui Xinsheng (Chairman). After increasing its holdings, the latest number of shares held by Rui Xinsheng was 6.228 million shares, and the shareholding ratio increased from 3.28% to 3.39%.
Changmao Biotech (00954.HK) received an increase of 304,000 shares from Chairman Rui Xinsheng
Gelonghui November 24 | According to the latest equity disclosure data from the Stock Exchange, on November 22, 2023, Changmao Biotech (00954.HK) received an increase of 304,000 shares at an average price of HK$0.5368 per share, involving approximately HK$163,200, by executive director Rui Xinsheng (Chairman). After increasing its holdings, the latest number of shares held by Rui Xinsheng was 6.032 million shares, and the shareholding ratio increased from 3.12% to 3.28%.
Changmao Biotech (00954.HK) received an increase of 596,000 shares from Chairman Rui Xinsheng
GLONGHUI November 21 | According to the latest equity disclosure data from the Stock Exchange, on November 17, 2023, Changmao Biotech (00954.HK) received an increase of 596,000 shares in the market by an average price of HK$0.5484 per share, involving approximately HK$326,800, with an average price of HK$0.5484 per share. After increasing its holdings, the latest number of shares held by Rui Xinsheng was 5.728 million shares, and the shareholding ratio increased from 2.79% to 3.12%.
Changmao Biochemical Unit Seeks 200 Million Yuan Bank Loan to Boost Factory Capacity
Changmao Biochemical Engineering (HKG:0954) subsidiary Changmao (Dalian) New Material will borrow up to 200 million yuan to partially finance the Phase II expansion of its production plant in Dalian C
CHANGMAO BIO: INTERIM REPORT 2023
Chang Mao Biotech (00954) released interim results. Profit attributable to shareholders was 4.157 million yuan, a year-on-year decrease of 90%
Chang Mao Biotech (00954) announced its results for the six months ended June 30, 2023, with revenue of 297 million yuan (...
CHANGMAO BIO: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
CHANGMAO BIO: PROFIT WARNING
Changmao Biotech (00954.HK) will hold a board meeting on August 18 to approve interim results
On August 1, GLONGHUI | Changmao Biotech (00954.HK) announced that the board meeting will be held on August 18, 2023 to discuss and approve the Group's unaudited interim results for the six months ended June 30, 2023, and consider the payment of dividends (if any).
Analysis
Price Target
No Data
